Christopher Towers - 04 Oct 2023 Form 4 Insider Report for INTELLIGENT BIO SOLUTIONS INC. (INBS)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
06 Oct 2023, 18:45:33 UTC
Prior SEC filing
17 Aug 2023
Next SEC filing
17 Nov 2023
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Christopher Towers

Key filing fact

Christopher Towers filed Form 4 for INTELLIGENT BIO SOLUTIONS INC. (INBS) on 06 Oct 2023.

Key facts

  • This page summarizes Christopher Towers's Form 4 filing for INTELLIGENT BIO SOLUTIONS INC. (INBS).
  • 3 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 06 Oct 2023, 18:45.

Change

  • Previous filing in this sequence was filed on 17 Aug 2023.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

INBS transaction

Common Stock

Purchase

Transaction value
Shares
+9,090
Change %
+1151%
Price
Shares after
9,880
Date
04 Oct 2023
Ownership
Direct
Footnotes
F1, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

INBS transaction Derivative

Common Stock Warrants (Series E)

Purchase

Transaction value
Shares
+9,090
Change %
Price
Shares after
9,090
Date
04 Oct 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
9,090
Exercise price
Footnotes
F1, F2
INBS transaction Derivative

Common Stock Warrants (Series F)

Purchase

Transaction value
Shares
+9,090
Change %
Price
Shares after
9,090
Date
04 Oct 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
9,090
Exercise price
Footnotes
F1, F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The reported securities are included within 9,090 INBS Class A Units purchased by the reporting person for $0.55 per Unit. Each Unit consists of one share of the common stock, one warrant to purchase one share of Common Stock at an exercise price of $0.55 per share ("Series E Warrants"), and one warrant to purchase one share of Common Stock at an exercise price of $0.55 per share ("Series F Warrants"). The Warrants will be exercisable beginning on the effective date of such stockholder approvals as may be required by the applicable rules and regulations of the Nasdaq Capital Market (or any successor entity) to permit the exercise of the Warrants ("Warrant Stockholder Approval").

Footnote F2

The exercise price of the Series E Warrants is $0.55 per share. However, under the one-time reset provision of the Series E Warrants, the exercise price of the Series E Warrants will reset to a price equal to the lesser of (i) the then exercise price and (ii) 90% of the five-day volume weighted average price for the five trading days immediately following the date the Company effects a reverse stock split.

Footnote F3

The exercise price of the Series F Warrants is $0.55 per share. However,under the alternate cashless exercise option of the Series F Warrants, the holder of the Series F Warrant (beginning on the date the Warrant Stockholder Approval is effective), has the right to receive an aggregate number of shares of Common Stock on a one-for-one basis (subject to adjustment).

Footnote F4

On February 9, 2023, the Issuer effected a 1-for-20 reverse stock split of its common stock (the "Reverse Split"). Unless otherwise noted, the amount of securities and purchase prices reported on this Form 4 have been adjusted to reflect the Reverse Split.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .